News early in last week was dominated by presentations at the American Society of Hematology (ASH) meeting. Among these was ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care ...

Calquence starts working as soon as you start taking it. But it can take time to see results on laboratory or imaging tests. You’ll likely continue taking Calquence for as long as it’s ...

Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to ...

Positive” results from the AMPLIFY Phase III trial showed AstraZeneca’s (AZN) Calquence in combination with venetoclax demonstrated a ...

Verition Fund Management LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 66.0% in the third ...

Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...

In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, ...